Directorate Change

Allergy Therapeutics PLC
07 November 2005



   Allergy Therapeutics plc strengthens board with experienced pharmaceutical
                            development professional

Allergy Therapeutics today announces the appointment to the board of Dr.
Virinder Nohria as a non-executive director.

Dr. Nohria, aged 51, works as a strategic consultant in international drug
development. He has lead teams in many successful interactions with regulatory
bodies in several countries, particularly the US FDA. Dr. Nohria served as Chief
Medical Officer and Vice President of Xcel Pharmaceuticals, Inc., a US specialty
pharmaceutical company until the sale of the company to Valeant Pharmaceutical
International in early 2005. Prior to joining Xcel, Dr. Nohria held several
positions in biotechnology and pharmaceutical companies including UCB Pharma and
Eli Lilly and Company. Dr. Nohria is a board certified paediatric neurologist
and received his medical degree from Cambridge University and doctorate in
neuropharmacology from University of Bradford. He is currently based in the US
and has affiliations with Emory and Duke Universities.

Ignace Goethals, Chairman of Allergy Therapeutics plc said:

"I am delighted that Virinder has agreed to join our board as a non-executive
director. His expertise in drug development and dealing with the FDA will be an
invaluable support to our excellent and growing internal R&D team as our new
MPL-based vaccines move through the late phases of clinical trials"

Virinder Nohria commented:

"Allergy Therapeutics is an emerging pharmaceutical company with a unique modern
pipeline in the interesting field of allergy vaccination with great potential.
There is real unmet medical need here and I look forward to being involved with
the company."

For further information:
Allergy Therapeutics                                         01903 844720
Keith Carter, Chief Executive

Bell Pottinger                                               020 7861 3232
Dan de Belder / Emma Charlton




                      This information is provided by RNS
            The company news service from the London Stock Exchange